
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA ISOTOPE & RADIATION CORPORATION

中國同輻股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability) (Stock Code: 1763)

VOLUNTARY ANNOUNCEMENT

XINJIANG HTA SUCCESSFULLY OBTAINED THE RADIATION SAFETY LICENSES FOR TECHNETIUM AND FLUORINE

This announcement is made on a voluntary basis by China Isotope & Radiation Corporation (the "**Company**") to keep shareholders and potential investors informed of the latest business developments of the Company.

The board of directors (the "**Board**") of the Company is pleased to announce that, recently, upon formal approval by the Department of Ecology and Environment of the Xinjiang Uygur Autonomous Region, Xinjiang HTA Pharmaceutical Co., Ltd. (the "**Xinjiang HTA**") has successfully obtained the radiation safety licenses for both technetium and fluorine (the "**Radiation Safety Licenses**"), and is the first radioisotopes production facility in Xinjiang region to have obtained the Radiation Safety Licenses.

The acquisition of the Radiation Safety Licenses has played a vital role in the future development of regional production and delivery centers for radiopharmaceuticals. In addition, it also serves as a technological and after-sales service platform for HTA Co., Ltd. ("HTA") to expand its businesses in Xinjiang; stabilising and expanding HTA's sales of other radiopharmaceuticals in Urumqi. At the same time, it also marks the filling of the gap in the production of radiopharmaceuticals in Xinjiang Uygur Autonomous Region, which is of great practical significance in promoting the development of nuclear medicine in Xinjiang, improving the safety of radiotherapy, and reducing the cost of medication for patients.

By order of the Board China Isotope & Radiation Corporation Zhang Junqi Chairman

Beijing, the PRC, 15 January 2024

As at the date of this announcement, the Board comprises Mr. Zhang Junqi, Mr. Xu Hongchao and Mr. Fan Guomin as executive Directors; Mr. Chen Shoulei, Mr. Ding Jianmin, Ms. Chang Jinyu and Ms. Liu Xiuhong as non-executive Directors; and Mr. Poon Chiu Kwok, Mr. Tian Jiahe, Ms. Chen Jingshan and Mr. Lu Chuang as independent non-executive Directors.